Localized Ewing Tumor of Bone: Final Results of the Cooperative Ewing’s Sarcoma Study CESS 86
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
PURPOSE: Cooperative Ewing’s Sarcoma Study (CESS) 86 aimed at improving event-free survival (EFS) in patients with high-risk localized Ewing tumor of bone. PATIENTS AND METHODS: We analyzed 301 patients recruited from January 1986 to July 1991 (60% male; median age 15 years). Tumors of volume >100 mL and/or at central-axis sites qualified patients for “high risk” (HR, n = 241), and small extremity lesions for “standard risk” (SR, n = 52). Standard-risk patients received 12 courses of vincristine, cyclophosphamide, and doxorubicin alternating with actinomycin D (VACA); HR patients received ifosfamide instead of cyclophosphamide (VAIA). Tumor sites were pelvis (27%), other central axis (28%), femur (19%), or other extremity (26%). The initial tumor volume was <100 mL in 33% of cases and ≥100 mL in 67%. Local therapy was surgery (23%), surgery plus radiotherapy (49%), or radiotherapy alone (28%). Event-free survival rates were estimated by Kaplan-Meier analyses, comparisons were done by log-rank test, and risk factors were analyzed by Cox models. RESULTS: On May 1, 1999 (median time under study, 133 months), the 10-year EFS was 0.52. Event-free survival did not differ between SR-VACA (0.52) and HR-VAIA (0.51, P = .92). Tumor volume of >200 mL (EFS, 0.36 v 0.63 for smaller tumors; P = .0001) and poor histologic response (EFS, 0.38 v 0.64 for good responders; P = .0007) had negative impacts on EFS. In multivariate analyses, small tumor volumes of <200 mL, good histologic response, and VAIA chemotherapy augured for fair outcome. Six of 301 patients (2%) died under treatment, and four patients (1.3%) developed second malignancies. CONCLUSION: Fifty-two percent of CESS 86 patients survived after risk-adapted therapy. High-risk patients seem to have benefited from intensified treatment that incorporated ifosfamide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Nesbit, M. E., Gehan, E. A., Burgert, E. O., Vietti, T. J., Cangir, A., Tefft, M., Evans, R., Thomas, P., Askin, F. B., & Kissane, J. M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.10.1664 · Cited by 570
Jürgens, H., Exner, U., Gadner, H., Harms, D., Michaelis, J., Sauer, R., Treuner, J., Voûte, T., Winkelmann, W., Winkler, K., et al. (1988) · Cancer · doi:10.1002/1097-0142(19880101)61:1<23::aid-cncr2820610106>3.0.co;2-m · Cited by 417
Self-citationBurgert, E. O., Nesbit, M. E., Garnsey, L. A., Gehan, E. A., Herrmann, J., Vietti, T. J., Cangir, A., Tefft, M., Evans, R., & Thomas, P. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1514 · Cited by 380
Bacci, G., Ferrari, S., Bertoni, F., Rimondini, S., Longhi, A., Bacchini, P., Forni, C., Manfrini, M., Donati, D., & Picci, P. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.4 · Cited by 327
Primary metastatic (stage IV) Ewing tumor: Survival analysis of 171 patients from the EICESS studies
Paulussen, M., Ahrens, S., Burdach, S., Craft, A., Dockhorn-Dworniczak, B., Dunst, J., Fröhlich, B., Winkelmann, W., Zoubek, A., & Jürgens, H. (1998) · Annals of Oncology · doi:10.1023/a:1008208511815 · Cited by 317
Self-citationMorphological grades of regression in osteosarcoma after polychemotherapy ? Study COSS 80
Salzer-Kuntschik, M., Delling, G., Beron, G., & Sigmund, R. (1983) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00625047 · Cited by 265
G�bel, V., J�rgens, H., Etsp�ler, G., Kemperdick, H., Jungblut, R. M., Stienen, U., & G�bel, U. (1987) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00391442 · Cited by 233
Self-citation
Cited by
O'Sullivan, B., Davis, A. M., Turcotte, R., Bell, R., Catton, C., Chabot, P., Wunder, J., Kandel, R., Goddard, K., Sadura, A., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09292-9 · Cited by 1,598
Grier, H. E., Krailo, M. D., Tarbell, N. J., Link, M. P., Fryer, C. J. H., Pritchard, D. J., Gebhardt, M. C., Dickman, P. S., Perlman, E. J., Meyers, P. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020890 · Cited by 1,328
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration
Gaspar, N., Hawkins, D. S., Dirksen, U., Lewis, I. J., Ferrari, S., Le Deley, M.-C., Kovar, H., Grimer, R., Whelan, J., Claude, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5256 · Cited by 722
Self-citationBalamuth, N. J., & Womer, R. B. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70286-4 · Cited by 686
The distinctive biology of cancer in adolescents and young adults
on behalf of the Biology and Clinical Trials Subgroups of the US National Cancer Institute Progress Review Group in Adolescent and Young Adult Oncology, Bleyer, A., Barr, R., Hayes-Lattin, B., Thomas, D., Ellis, C., & Anderson, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2349 · Cited by 660
Esiashvili, N., Goodman, M., & Marcus, R. B. (2008) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31816e22f3 · Cited by 582
Ewing's Sarcoma Family of Tumors: Current Management
Bernstein, M., Kovar, H., Paulussen, M., Randall, R. L., Schuck, A., Teot, L. A., & Juergensg, H. (2006) · The Oncologist · doi:10.1634/theoncologist.11-5-503 · Cited by 520
Self-citationSchuck, A., Ahrens, S., Paulussen, M., Kuhlen, M., Könemann, S., Rübe, C., Winkelmann, W., Kotz, R., Dunst, J., Willich, N., et al. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03797-5 · Cited by 348
Self-citationRisk of recurrence and survival after relapse in patients with Ewing sarcoma
Stahl, M., Ranft, A., Paulussen, M., Bölling, T., Vieth, V., Bielack, S., Görtitz, I., Braun‐Munzinger, G., Hardes, J., Jürgens, H., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23040 · Cited by 315
Self-citationDuchman, K. R., Gao, Y., & Miller, B. J. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.05.001 · Cited by 305
NCCN Guidelines Insights: Bone Cancer, Version 2.2017
Biermann, J. S., Chow, W., Reed, D. R., Lucas, D., Adkins, D. R., Agulnik, M., Benjamin, R. S., Brigman, B., Budd, G. T., Curry, W. T., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0017 · Cited by 294
Xu, N., Wei, F., Liu, X., Jiang, L., Cai, H., Li, Z., Yu, M., Wu, F., & Liu, Z. (2016) · SPINE · doi:10.1097/brs.0000000000001179 · Cited by 291
Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Zöllner, S. K., Amatruda, J. F., Bauer, S., Collaud, S., de Álava, E., DuBois, S. G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081685 · Cited by 271
Paulussen, M., Craft, A. W., Lewis, I., Hackshaw, A., Douglas, C., Dunst, J., Schuck, A., Winkelmann, W., Köhler, G., Poremba, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5720 · Cited by 263
Self-citation
Metadata
- Authors
- Paulussen, M., Ahrens, S., Dunst, J., Winkelmann, W., Exner, G. U., Kotz, R., Amann, G., Dockhorn-Dworniczak, B., Harms, D., Müller-Weihrich, S., Welte, K., Kornhuber, B., Janka-Schaub, G., Göbel, U., Treuner, J., Voûte, P. A., Zoubek, A., Gadner, H., & Jürgens, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-03-15
- Volume
- 19
- Issue
- 6
- Pages
- 1818-1829
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2154211764
- Cited by
- 445
- References
- 20
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.